Diverse oncological patients with a clinically challenging situation., Oesophagogastric adenocarcinoma (OGA), Pancreatic ductal adenocarcinoma (PDAC)
Conditions
Brief summary
OGA: detection ratio for lymph node and distant metastases (combined)., PDAC: detection ratio for lymph node and distant metastases (combined)., Clinically Challenging Situation: fraction of patients were scan was deemed contributory. This means: 1. [18F]AlF-FAPI-74 identifies a lesion as malignant (true positive) with effective upstaging. 2. [18F]AlF-FAPI-74 identifies a lesion as non-malignant (true negative) with effective downstaging. 3. [18F]AlF-FAPI-74 can differentiate between a malignant or non-malignant lesion when there is doubt. 4. Other implications that are deemed contributory by the treating physician.
Detailed description
See trial synopsis
Interventions
DRUGTelebrix Gastro
DRUG300 mg I/ml
DRUGoplossing voor orale of rectale toediening
Sponsors
UZ Leuven
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OGA: detection ratio for lymph node and distant metastases (combined)., PDAC: detection ratio for lymph node and distant metastases (combined)., Clinically Challenging Situation: fraction of patients were scan was deemed contributory. This means: 1. [18F]AlF-FAPI-74 identifies a lesion as malignant (true positive) with effective upstaging. 2. [18F]AlF-FAPI-74 identifies a lesion as non-malignant (true negative) with effective downstaging. 3. [18F]AlF-FAPI-74 can differentiate between a malignant or non-malignant lesion when there is doubt. 4. Other implications that are deemed contributory by the treating physician. | — |
Secondary
| Measure | Time frame |
|---|---|
| See trial synopsis | — |
Countries
Belgium
Outcome results
None listed